Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
Public ClinicalTrials.gov record NCT01318694. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination With Peg-IFNα2a and Ribavirin in Hepatitis C Genotype 1 Treatment-naïve Patients
Study identification
- NCT ID
- NCT01318694
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Debiopharm International SA
- Industry
- Enrollment
- 1,081 participants
Conditions and interventions
Conditions
Interventions
- ALV Placebo Drug
- Alisporivir Drug
- Peginterferon alfa-2a Drug
- Ribavirin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2011
- Primary completion
- Jul 31, 2013
- Completion
- Jul 31, 2013
- Last update posted
- Sep 29, 2016
2011 – 2013
United States locations
- U.S. sites
- 32
- U.S. states
- 15
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Beverly Hills | California | 90211 | — |
| Novartis Investigative Site | Oakland | California | 94612 | — |
| Novartis Investigative Site | San Diego | California | 92101 | — |
| Novartis Investigative Site | San Diego | California | 92123 | — |
| Novartis Investigative Site | San Diego | California | 92128 | — |
| Novartis Investigative Site | Ventura | California | 93003 | — |
| Novartis Investigative Site | Bradenton | Florida | 34209 | — |
| Novartis Investigative Site | Maitland | Florida | 32751 | — |
| Novartis Investigative Site | Tampa | Florida | 33607 | — |
| Novartis Investigative Site | Springfield | Illinois | 62703 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46237 | — |
| Novartis Investigative Site | Shreveport | Louisiana | 71130-3932 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21202 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21229 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55404 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | St Louis | Missouri | 63128 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68198 | — |
| Novartis Investigative Site | Newark | New Jersey | 07102 | — |
| Novartis Investigative Site | Brooklyn | New York | 11230 | — |
| Novartis Investigative Site | New York | New York | 10016 | — |
| Novartis Investigative Site | New York | New York | 10021 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28203 | — |
| Novartis Investigative Site | Fayetteville | North Carolina | 28304 | — |
| Novartis Investigative Site | Arlington | Texas | 76012 | — |
| Novartis Investigative Site | Dallas | Texas | 75246-2096 | — |
| Novartis Investigative Site | Dallas | Texas | 75390 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | San Antonio | Texas | 78215 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84124 | — |
| Novartis Investigative Site | Fairfax | Virginia | 22031 | — |
| Novartis Investigative Site | Newport News | Virginia | 23602 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01318694, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2016 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01318694 live on ClinicalTrials.gov.